Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

J&J expects data for U.S. authorization of COVID-19 vaccine by Feb, says head scientist

11/17/2020 | 03:00pm EST

Nov 17 (Reuters) - Johnson & Johnson's chief scientist said the drugmaker is recruiting over 1,000 people per day for the late-stage trial of its experimental COVID-19 vaccine and expects to have all the data needed to seek U.S. authorization by February or earlier.

"By the end of the year or around the end of the year, we should have 60,000 people in the study," Dr. Paul Stoffels, J&J's chief scientific officer, said in an interview ahead of this week's Reuters Total Health conference.

"And efficacy endpoint should be there in the first few weeks or months, January or February, of the new year," he added.

The Phase III trial of the single-dose vaccine started in late September. The company paused the trial in October because of a serious medical event in one participant and resumed after getting the green light from an independent safety panel.

J&J must provide safety data to the U.S. Food and Drug Administration for at least one-half of trial participants for a duration of two months after they receive the vaccine. "So that will bring us around the year end or early next year for having all the data," he added.

J&J lags some of its rivals in the global race to develop a safe and effective vaccine against the virus that has killed over 1.3 million people worldwide and roiled the global economy.

Rival Moderna on Monday said its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, following similar results from Pfizer last week.

Both Pfizer's and Moderna's vaccines use a new technology known as messenger RNA, or mRNA. By contrast, J&J's vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger the body's immune system.

J&J's candidate is a single-dose vaccine, whereas the vaccines from Moderna and Pfizer and another under development by AstraZeneca all require two shots separated by several weeks.

"In a pandemic a single shot is definitely important globally," Stoffels said. "(A two-shot vaccine) is a very significant operational challenge. More so in healthcare systems which are less well organized."

Single-shot vaccines will likely benefit in particular remote areas, Stoffels said.

For more on Reuters Events Total Health click here: https://reutersevents.com/events/healthcare/

(Reporting by Manojna Maddipatla in Bengaluru and Axel Threlfall in London; Editing by Bill Berkrot and Rosalba O'Brien)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
JOHNSON & JOHNSON 1.13% 163.55 Delayed Quote.3.92%
MODERNA, INC. -1.47% 131.02 Delayed Quote.25.41%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
All news about MODERNA, INC.
01:40aJapanese shares gain tracking U.S. futures; tech and pharma stocks boost
RE
01/24TATA IN TALKS TO LAUNCH MODERNA COVI : Et
RE
01/24Japanese shares track U.S. futures higher, tech leads gains
RE
01/24MODERNA : U.S. CDC says 21.8 million doses of COVID-19 vaccines administered
RE
01/23MODERNA : U.S. CDC says 41.4 mln doses of COVID-19 vaccines distributed, 20.5 ml..
RE
01/22PFIZER : Provinces doing 'extraordinary' job to avoid wasting doses of COVID-19 ..
AQ
01/2239.9 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
RE
01/22CDC : 10 life-threatening reactions linked with Moderna COVID-19 vaccine
AQ
01/22MODERNA : Lucky few hit COVID-19 vaccine jackpot for rare extra doses
AQ
01/22MODERNA : Severe allergic reactions to Moderna vaccine appear rare -CDC report
RE
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -107x
Yield 2020 -
Capitalization 51 846 M 51 846 M -
EV / Sales 2020 96,2x
EV / Sales 2021 4,40x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,27 $
Last Close Price 131,02 $
Spread / Highest target 41,2%
Spread / Average Target 4,77%
Spread / Lowest Target -47,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%24 266